Phase I Study of Lapatinib and Pemetrexed in the Second-Line Treatment of Advanced or Metastatic Non-Small-Cell Lung Cancer With Assessment of Circulating Cell Free Thymidylate Synthase RNA as a Potential Biomarker

Lapatinib and pemetrexed was well tolerated, and data suggest a similar response rate to pemetrexed monotherapy.